Research
Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation
-
* Corresponding author: Marya D Zilberberg mzilberb@schoolph.umass.edu
1 School of Public Health and Health Sciences, University of Massachusetts, Arnold House, 715 North Pleasant Street, Amherst, MA 01003, USA
2 EviMed Research Group, LLC, PO Box 303, Goshen, MA 01032, USA
3 Health Economics and Outcomes Research, Astellas Pharma US, Inc., 3 Parkway North, Deerfield, IL 60015, USA
4 Division of Pulmonary and Critical Care, Washington Hospital Center, 100 Irving Street NW, Washington, DC 20010, USA
Critical Care 2009, 13:R94 doi:10.1186/cc7924
See related commentary by Golan, http://ccforum.com/content/13/4/180
Published: 19 June 2009Additional files
Additional data file 1:
Table S1 lists the input sources for estimating the prevalence of nosocomial candidemia in critically ill patients. Table S2 lists the input sources for estimating the prevalence of Candida krusei and Candida glabrata as a proportion of all nosocomial candidemia in critically ill patients.
Format: DOC Size: 37KB Download file
This file can be viewed with: Microsoft Word Viewer
